{"pub": "investing.com", "url": "https://au.investing.com/news/stock-market-news/brieffda-grants-orphan-drug-designation-for-neurens-nnz2591-to-treat-angelman-phelanmcdermid-and-pitt-hopkins-syndromes-1973911", "downloaded_at": "2019-10-17 10:33:16.048308+00:00", "title": "BRIEF-FDA Grants Orphan Drug Designation For Neuren's NNZ-2591 To Treat Angelman, Phelan-Mcdermid And Pitt Hopkins Syndromes", "language": "en", "text": "BRIEF-FDA Grants Orphan Drug Designation For Neuren's NNZ-2591 To Treat Angelman, Phelan-Mcdermid And Pitt Hopkins Syndromes\n\nStock Markets 19 minutes ago (Oct 17, 2019 21:14)\n\n\u00a9 Reuters. BRIEF-FDA Grants Orphan Drug Designation For Neuren's NNZ-2591 To Treat Angelman, Phelan-Mcdermid And Pitt Hopkins Syndromes Oct 17 (Reuters) - Neuren Pharmaceuticals Ltd : * FDA GRANTS ORPHAN DRUG DESIGNATION FOR NEUREN'S NNZ-2591 TO TREAT ANGELMAN, PHELAN-MCDERMID AND PITT HOPKINS SYNDROMES\n\nBRIEF-FDA Grants Orphan Drug Designation For Neuren's NNZ-2591 To Treat Angelman, Phelan-Mcdermid And Pitt Hopkins Syndromes", "description": "BRIEF-FDA Grants Orphan Drug Designation For Neuren's NNZ-2591 To Treat Angelman, Phelan-Mcdermid And Pitt Hopkins Syndromes", "authors": [], "top_image": "https://i-invdn-com.akamaized.net/news/LYNXMPEB230DM_L.jpg", "published_at": "2019-10-17"}